MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies

MAIA Biotechnology, Inc.

Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.
Preclinical data showed ateganosine highly synergistic and effective with anti-PD-L1 agent atezolizumab.
Ateganosine is a first-in-class telomere-targeting agent in clinical development for NSCLC after checkpoint inhibitor progression.
CEO Vlad Vitoc said partnership with Roche strengthens mission to find safe and effective cancer treatments.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.